0000000000082727

AUTHOR

Manickam Janakiraman

showing 1 related works from this author

Clinical and genomic alternations predictive of response to sunitinib in patients with advanced renal cell carcinoma.

2016

e16109Background: Sunitinib is a 1st-line therapy for clear cell Renal Cell Carcinoma (ccRCC); however, 20-30% of tumors show primary resistant disease with progression as the best response. This s...

OncologyCancer Researchmedicine.medical_specialtySunitinibbusiness.industryDiseaseurologic and male genital diseasesmedicine.diseaseClear cell renal cell carcinomaOncologyRenal cell carcinomaInternal medicinemedicineIn patientbusinessmedicine.drugJournal of Clinical Oncology
researchProduct